Eli Lilly says Zepbound cut weight 20.2% over 72 weeks, beating Wegovy's 13.7% in adults with obesity

Eli Lilly said its dual GIP and GLP-1 receptor agonist Zepbound delivered 20.2% weight loss over 72 weeks versus 13.7% for Wegovy in adults with obesity, with the 10 mg and 15 mg doses showing greater reduction than Wegovy HD.

Detected & updated continuously · Source: Nebula